Aside from MET exon 14 skip mutations, are there other targetable MET mutations or fusions that you would consider for TKI therapy?
Would you reserve TKI for after standard of care chemotherapy and immunotherapy or consider earlier line of treatment?
Answer from: Medical Oncologist at Community Practice
MET exon 14 skipping mutations are a heterogeneous group of mutations that result in the absence of a juxtamembrane domain leading to constitutive activity of the MET receptor. Over 100 genetic variants have been described. In addition to MET exon 14 skipping mutations, MET amplification has also be...
Sign in or Register to read more